Innolab
Santiago, 7510491, Chile
NCT Number: NCT04230070
This Pivotal study will investigate the bioavailability in women of 2 tablet formulations containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The Pivotal study will be performed at a single site with 30 subjects. Participants will take 2 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 14 days between each study period.
Looking for future studies?
Notify Me18 year–55 year
Female
Interventional
Phase 1
Santiago, 7510491, Chile
The primary objective of the study is to investigate the relative bioavailability of Levonorgestrel and Ethinyl estradiol of 2 tablet formulations with Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg and to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption:
Participants will be confined in the study site for approximately 36 hours during each study period (for 12 hours pre-dosing and for 24 hours post dosing) during which pharmacokinetic (PK) blood samples will be obtained. 16 blood samples will be taken up to 24 hours after the administration in each period. Participants will return to the site to provide additional blood samples at 48 h, and 72 h postdose.
The washout period between the two study periods will be at least 14 days. The samples from each participant will be analyzed with 2 methods of highperformance liquid chromatography-tandem mass spectrometry bioanalytical assays to quantify total Levonorgestrel and Ethinyl estradiol in plasma.
The safety objective is to evaluate the tolerability of both formulations in women by collecting adverse events.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bioequivalence
Other names: Investigational Medicinal Product
Bioequivalence
Other names: Microgynon CD (Trademark)
Time frame: From tablet intake and up to 72 hours after tablet intake
19 samples up to 72 hours will be taken after the administration in each period.
Time frame: From tablet intake and up to 72 hours after tablet intake
19 samples up to 72 hours will be taken after the administration in each period
Time frame: From tablet intake and up to 72 hours after tablet intake
19 samples up to 72 hours will be taken after the administration in each period
Time frame: From tablet intake and up to 72 hours after tablet intake
19 samples up to 72 hours will be taken after the administration in each period
Time frame: From tablet intake and up to 72 hours after tablet intake
19 samples up to 72 hours will be taken after the administration in each period
Time frame: From tablet intake and up to 72 hours after tablet intake
19 samples up to 72 hours will be taken after the administration in each period
Time frame: From tablet intake and up to 72 hours after tablet intake
19 samples up to 72 hours will be taken after the administration in each period
Time frame: From tablet intake and up to 72 hours after tablet intake
19 samples up to 72 hours will be taken after the administration in each period
Laboratorios Andromaco S.A.
Industry
Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 15.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07698288
Bioequivalence
Mexico City, Mexico
View Trial DetailsNCT06987773
Bioequivalence
Toronto, Ontario, Canada
View Trial DetailsNCT07345130
Bioavailability, Bioequivalence
Las Vegas, Nevada, United States
View Trial DetailsNCT07393022
Bioequivalence, Health Adult Subjects
Toronto, Ontario, Canada
View Trial Details